2012
DOI: 10.1007/s00415-012-6750-9
|View full text |Cite
|
Sign up to set email alerts
|

Erratum to: Treatment of essential tremor: a systematic review of evidence and recommendations from the Italian Movement Disorders Association

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
4
0

Year Published

2013
2013
2023
2023

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(4 citation statements)
references
References 0 publications
0
4
0
Order By: Relevance
“…Previous studies have shown that the initial dose of short‐acting propranolol was 10 mg twice/thrice a day, gradually increased to 20–30 mg thrice daily, and the maintenance dose was 10–320 mg/day (Ferreira et al., 2019). Furthermore, published controlled trials have shown that propranolol at a dose of 120–240 mg/day has been suggested to elicit a clinically therapeutic effect, and the most common interview period ranged from 2 weeks to 1 month (Ferreira et al., 2019; Schneider & Deuschl, 2014; Sharma & Pandey, 2020; Zappia et al., 2013). Nevertheless, the clinical response to propranolol treatment was highly variable.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Previous studies have shown that the initial dose of short‐acting propranolol was 10 mg twice/thrice a day, gradually increased to 20–30 mg thrice daily, and the maintenance dose was 10–320 mg/day (Ferreira et al., 2019). Furthermore, published controlled trials have shown that propranolol at a dose of 120–240 mg/day has been suggested to elicit a clinically therapeutic effect, and the most common interview period ranged from 2 weeks to 1 month (Ferreira et al., 2019; Schneider & Deuschl, 2014; Sharma & Pandey, 2020; Zappia et al., 2013). Nevertheless, the clinical response to propranolol treatment was highly variable.…”
Section: Discussionmentioning
confidence: 99%
“…Existing studies indicate that propranolol and primidone remain the preferred oral agents for ET, and propranolol can significantly reduce the amplitude of tremor (Schneider & Deuschl, 2014), although there is no correlation between the blood concentration of propranolol and its effectiveness in suppressing tremor (Koller, 1986). Propranolol is considered to be an effective therapy for ET of the upper extremity according to the evidence‐based ET treatment guidelines from the American Academy of Neurology (Zesiewicz et al., 2011), the MDS Task Force on Tremor (Ferreira et al., 2019), and the Italian Movement Disorders Association (Zappia et al., 2013), but it has shown only a slight or no effect on head tremors (Paparella et al., 2018). Various clinical trials and consensus have shown that 50%–70% of ET patients’ symptoms improve with propranolol (Ondo, 2006).…”
Section: Introductionmentioning
confidence: 99%
“…ET has been treated with diverse methods such as propranolol, primidone, topiramate, clozapine, Botulinum toxin type A, thalamic deep-brain stimulation (DBS), subthalamic nucleus DBS, and so on [4]. …”
Section: Introductionmentioning
confidence: 99%
“…Appropriate measurement of these constructs will ultimately influence patient care, intervention, and service prescription, as well as policy, and funding decisions (Hobart, 2003; Hobart et al, 2007). In the context of tremor disorders, clinicians, and researchers do not always measure activity limitations (Gorman et al, 1986; Sasso et al, 1991; Obwegeser et al, 2001; Vaillancourt et al, 2003; Fox et al, 2004; Van Der Walt et al, 2012), or they use tools with poor, unknown, or inadequate measurement properties for the targeted population (Herzog et al, 2003; Flora et al, 2010; Thevathasan et al, 2011; Ohye et al, 2012; Zappia et al, 2013). …”
mentioning
confidence: 99%